Ausgabe 1/2015
Inhalt (36 Artikel)
Reduced progesterone levels explain the reduced risk of breast cancer in obese premenopausal women: a new hypothesis
Mitch Dowsett, Elizabeth Folkerd
HER2-family signalling mechanisms, clinical implications and targeting in breast cancer
N. Elster, D. M. Collins, S. Toomey, J. Crown, A. J. Eustace, B. T. Hennessy
Stearidonic acid-enriched flax oil reduces the growth of human breast cancer in vitro and in vivo
K. Subedi, H.-M. Yu, M. Newell, R. J. Weselake, D. Meesapyodsuk, X. Qiu, S. Shah, C. J. Field
Inherited predisposition to breast cancer among African American women
Jane E. Churpek, Tom Walsh, Yonglan Zheng, Zakiya Moton, Anne M. Thornton, Ming K. Lee, Silvia Casadei, Amanda Watts, Barbara Neistadt, Matthew M. Churpek, Dezheng Huo, Cecilia Zvosec, Fang Liu, Qun Niu, Rafael Marquez, Jing Zhang, James Fackenthal, Mary-Claire King, Olufunmilayo I. Olopade
A genetic variant at 12p11 significantly modifies breast cancer risk in a genetically homogenous island population
Terri Patricia McVeigh, Una Mary McVeigh, Karl J. Sweeney, Michael J. Kerin, Nicola Miller
Obesity-associated systemic interleukin-6 promotes pre-adipocyte aromatase expression via increased breast cancer cell prostaglandin E2 production
Laura W. Bowers, Andrew J. Brenner, Stephen D. Hursting, Rajeshwar R. Tekmal, Linda A. deGraffenried
Sphingosine kinase 1 contributes to leptin-induced STAT3 phosphorylation through IL-6/gp130 transactivation in oestrogen receptor-negative breast cancer
Heba Alshaker, Qi Wang, Adam E. Frampton, Jonathan Krell, Jonathan Waxman, Mathias Winkler, Justin Stebbing, Colin Cooper, Ernesto Yagüe, Dmitri Pchejetski
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer
Jennifer R. Bean, Sarah R. Hosford, Lynn K. Symonds, Philip Owens, Lloye M. Dillon, Wei Yang, Kevin Shee, Gary N. Schwartz, Jonathan D. Marotti, Kristen E. Muller, Kari M. Rosenkranz, Richard J. Barth, Vivian S. Chen, Veena R. Agarwal, Todd W. Miller
HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts
Patricia de Cremoux, Mathieu Dalvai, Olivia N’Doye, Fatima Moutahir, Gaëlle Rolland, Olfa Chouchane-Mlik, Franck Assayag, Jacqueline Lehmann-Che, Laurence Kraus-Berthie, André Nicolas, Brian Paul Lockhart, Elisabetta Marangoni, Hugues de Thé, Stéphane Depil, Kerstin Bystricky, Didier Decaudin
Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors
Elizabeth S. Yeh, Melissa A. Abt, Elizabeth G. Hill
In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer
Yuqi Jing, Marcela Toro Bejarano, Julia Zaias, Jaime R. Merchan
Effects of the BEAT Cancer physical activity behavior change intervention on physical activity, aerobic fitness, and quality of life in breast cancer survivors: a multicenter randomized controlled trial
Laura Q. Rogers, Kerry S. Courneya, Philip M. Anton, Patricia Hopkins-Price, Steven Verhulst, Sandra K. Vicari, Randall S. Robbs, Robert Mocharnuk, Edward McAuley
Expression profiling of circulating tumor cells in metastatic breast cancer
Julie E. Lang, Janet H. Scott, Denise M. Wolf, Petr Novak, Vasu Punj, Mark Jesus M. Magbanua, Weizhu Zhu, Neal Mineyev, Christopher M. Haqq, Julia R. Crothers, Laura J. Esserman, Debasish Tripathy, Laura van ’t Veer, John W. Park
Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast
Jing Liu, Yang Yu, Jing-yan Sun, Shan-shan He, Xin Wang, Jian Yin, Xu-chen Cao
Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer
Hans-Joachim Lück, Kristina Lübbe, Mattea Reinisch, Nicolai Maass, Gabriele Feisel-Schwickardi, Oliver Tomé, Wolfgang Janni, Mustafa Aydogdu, Tanja Neunhöffer, Angelika Ober, Bahriye Aktas, Tjoung-Won Park-Simon, Claudia Schumacher, Heinz-Gert Höffkes, Thomas Illmer, Harald Wagner, Keyur Mehta, Gunter von Minckwitz, Valentina Nekljudova, Sibylle Loibl
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
Sara Tolaney, Howard Burris, Elaina Gartner, Ingrid A. Mayer, Cristina Saura, Matthew Maurer, Eva Ciruelos, Agustin A. Garcia, Frank Campana, Bin Wu, Yi Xu, Jason Jiang, Eric Winer, Ian Krop
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study
A. R. Tan, H. Johannes, P. Rastogi, S. A. Jacobs, A. Robidoux, P. J. Flynn, M. P. Thirlwell, L. Fehrenbacher, P. J. Stella, R. Goel, T. B. Julian, L. Provencher, M. J. Bury, K. Bhatt, C. E. Geyer Jr., S. M. Swain, E. P. Mamounas, N. Wolmark
Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer
Michael R. Clemens, Oleg A. Gladkov, Elaina Gartner, Vladimir Vladimirov, John Crown, Joyce Steinberg, Fei Jie, Anne Keating
Single-nucleotide polymorphisms in DNA bypass polymerase genes and association with breast cancer and breast cancer subtypes among African Americans and Whites
Leila Family, Jeannette T. Bensen, Melissa A. Troester, Michael C. Wu, Carey K. Anders, Andrew F. Olshan
Incidence of breast cancer in a cohort of 5,135 transgender veterans
George R. Brown, Kenneth T. Jones
Geographic access and age-related variation in chemotherapy use in elderly with metastatic breast cancer
Shaowei Wan, Steven Jubelirer
Toward the breast screening balance sheet: cumulative risk of false positives for annual versus biennial mammograms commencing at age 40 or 50
Caleb J. Winch, Kerry A. Sherman, John Boyages
Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry
Eric Rosenthal, Kelsey Moyes, Christopher Arnell, Brent Evans, Richard J. Wenstrup
Reduced risk of axillary lymphatic spread in triple-negative breast cancer
Emil Villiam Holm-Rasmussen, Maj-Britt Jensen, Eva Balslev, Niels Kroman, Tove Filtenborg Tvedskov
Breast cancer risk after diagnosis by screening mammography of nonproliferative or proliferative benign breast disease: a study from a population-based screening program
Xavier Castells, Laia Domingo, Josep María Corominas, Isabel Torá-Rocamora, María Jesús Quintana, Marisa Baré, Carmen Vidal, Carmen Natal, Mar Sánchez, Francina Saladié, Joana Ferrer, Mar Vernet, Sonia Servitja, Ana Rodríguez-Arana, Marta Roman, Josep Alfons Espinàs, María Sala
Immunoassay and Nb2 lymphoma bioassay prolactin levels and mammographic density in premenopausal and postmenopausal women the Nurses’ Health Studies
Megan S. Rice, Shelley S. Tworoger, Kimberly A. Bertrand, Susan E. Hankinson, Bernard A. Rosner, Yvonne B. Feeney, Charles V. Clevenger, Rulla M. Tamimi
Pregnancy-associated breast cancer in women from Shanghai: risk and prognosis
Kathrin Strasser-Weippl, Ritesh Ramchandani, Lei Fan, Junjie Li, Marc Hurlbert, Dianne Finkelstein, Zhi-Ming Shao, Paul E. Goss
No effect of scalp cooling on survival among women with breast cancer
J. Lemieux, L. Provencher, L. Perron, J. Brisson, C. Amireault, C. Blanchette, E. Maunsell
Fulvestrant and male breast cancer: a pooled analysis
Flora Zagouri, Theodoros N. Sergentanis, Dimosthenis Chrysikos, Meletios-Athanasios Dimopoulos, Theodora Psaltopoulou
Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis
Naoki Hayashi, Naoki Niikura, Norikazu Masuda, Seiki Takashima, Rikiya Nakamura, Ken-ichi Watanabe, Chizuko Kanbayashi, Mayumi Ishida, Yasuo Hozumi, Michiko Tsuneizumi, Naoto Kondo, Yoichi Naito, Yayoi Honda, Akira Matsui, Tomomi Fujisawa, Risa Oshitanai, Hiroyuki Yasojima, Hideko Yamauchi, Shigehira Saji, Hiroji Iwata
Greater absolute risk for all subtypes of breast cancer in the US than Malaysia
Hisani N. Horne, C. R. Beena Devi, Hyuna Sung, Tieng Swee Tang, Philip S. Rosenberg, Stephen M. Hewitt, Mark E. Sherman, William F. Anderson, Xiaohong R. Yang
Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications
Katarzyna J. Jerzak, Jessica Cockburn, Gregory R. Pond, Kathleen I. Pritchard, Steven A. Narod, Sukhbinder K. Dhesy-Thind, Anita Bane
Confocal fluorescence microscopy for rapid evaluation of invasive tumor cellularity of inflammatory breast carcinoma core needle biopsies
Jessica Dobbs, Savitri Krishnamurthy, Matthew Kyrish, Ana Paula Benveniste, Wei Yang, Rebecca Richards-Kortum
Erratum to: Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer
Ben P. Haynes, Giuseppe Viale, Viviana Galimberti, Nicole Rotmensz, Bianca Gibelli, Ian E. Smith, Mitch Dowsett
Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
Chris Twelves, Javier Cortes, Linda Vahdat, Martin Olivo, Yi He, Peter A. Kaufman, Ahmad Awada